Cytovia Therapeutics

Share on: 

Cytovia aims to accelerate patient access to transformational cell therapies and immunotherapies. Cytovia primarily focuses on Natural Killer (NK) cell biology and pluripotent stem cell (iPSC) platform for NK cell therapy, gene editing of Chimeric Antigen Receptors (CAR) to enhance targeting of NK cells, and NK engager multi-functional antibodies.

COVID-19: 04/2020, Partners with MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)

Brickell Bayview Center 80 SW 8th Street
Miami FL 33130
United States